Yokogawa Electric Corporation has acquired a nanopipette*1 technology that was developed by BioStinger, Inc., a spin-off from the University of California, Santa Cruz. This technology is able to target specific locations inside individual cells, enabling the injection of target substances such as genes or drugs and the extraction of intracellular materials.
The low invasiveness of this technology to cells enables more detailed analysis of live single cells, organelles, and cytoplasmic components.